GLENMARKPharmaceuticals
Glenmark Pharmaceuticals Ltd — Cash Flow Statement
₹2170.50
+0.82%
Glenmark Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -1.58K Cr | -1.16K Cr | 17.63 Cr | 318.54 Cr | — |
| Repayment Of Debt | -140.68 Cr | -3.65K Cr | -513.22 Cr | -3.02K Cr | — |
| Issuance Of Debt | 507.24 Cr | 0.00 | 1.16K Cr | 2.13K Cr | — |
| Issuance Of Capital Stock | 0.00 | 1.20 Cr | 0.00 | 1.01K Cr | — |
| Capital Expenditure | -749.57 Cr | -898.38 Cr | -607.76 Cr | -790.12 Cr | — |
| End Cash Position | 1.68K Cr | 1.66K Cr | 1.44K Cr | 1.41K Cr | — |
| Beginning Cash Position | 1.66K Cr | 1.44K Cr | 1.41K Cr | 1.14K Cr | — |
| Effect Of Exchange Rate Changes | 55.89 Cr | 17.68 Cr | 12.39 Cr | 17.55 Cr | — |
| Changes In Cash | -38.46 Cr | 389.32 Cr | 19.45 Cr | 254.88 Cr | — |
| Financing Cash Flow | 787.04 Cr | -3.91K Cr | -77.46 Cr | -520.49 Cr | — |
| Interest Paid Cff | -190.78 Cr | -516.78 Cr | -311.54 Cr | -250.51 Cr | — |
| Cash Dividends Paid | -70.44 Cr | -117.75 Cr | -136.61 Cr | -92.69 Cr | — |
| Net Common Stock Issuance | 0.00 | 1.20 Cr | 0.00 | 1.01K Cr | — |
| Common Stock Issuance | 0.00 | 1.20 Cr | 0.00 | 1.01K Cr | — |
| Net Issuance Payments Of Debt | 1.20K Cr | -3.17K Cr | 629.97 Cr | -1.03K Cr | — |
| Net Short Term Debt Issuance | 833.95 Cr | 481.12 Cr | -20.00 Cr | -141.71 Cr | — |
| Net Long Term Debt Issuance | 366.56 Cr | -3.65K Cr | 649.97 Cr | -889.09 Cr | — |
| Long Term Debt Payments | -140.68 Cr | -3.65K Cr | -513.22 Cr | -3.02K Cr | — |
| Long Term Debt Issuance | 507.24 Cr | 0.00 | 1.16K Cr | 2.13K Cr | — |
| Investing Cash Flow | 2.09 Cr | 4.56K Cr | -528.49 Cr | -333.28 Cr | — |
| Net Other Investing Changes | -28.61 Cr | -16.63 Cr | -0.07 Cr | 455.60 Cr | — |
| Interest Received Cfi | 42.12 Cr | 17.16 Cr | 22.77 Cr | 9.32 Cr | — |
| Dividends Received Cfi | 60000.00 | 20000.00 | 0.35 Cr | 0.35 Cr | — |
| Net Investment Purchase And Sale | -9.30 Cr | 7.05 Cr | -1.01 Cr | -10.02 Cr | — |
| Sale Of Investment | 2.45 Cr | 7.05 Cr | 5.00 Cr | 30.00 Cr | — |
| Purchase Of Investment | -11.75 Cr | 0.00 | -6.01 Cr | -40.02 Cr | — |
| Net Business Purchase And Sale | 745.03 Cr | 5.45K Cr | 0.00 | — | — |
| Sale Of Business | 745.03 Cr | 5.45K Cr | 0.00 | — | — |
| Net PPE Purchase And Sale | -747.15 Cr | -896.30 Cr | -550.53 Cr | -788.54 Cr | — |
| Sale Of PPE | 2.42 Cr | 2.08 Cr | 57.23 Cr | 1.58 Cr | — |
| Purchase Of PPE | -749.57 Cr | -898.38 Cr | -607.76 Cr | -790.12 Cr | — |
| Operating Cash Flow | -827.60 Cr | -265.44 Cr | 625.39 Cr | 1.11K Cr | — |
| Taxes Refund Paid | -680.13 Cr | -1.05K Cr | -640.54 Cr | -558.44 Cr | — |
| Change In Working Capital | -2.53K Cr | -796.95 Cr | -1.07K Cr | -561.26 Cr | — |
| Change In Other Current Assets | 156.20 Cr | -518.19 Cr | -16.77 Cr | 106.67 Cr | — |
| Change In Payable | -813.75 Cr | -734.41 Cr | 166.21 Cr | 84.76 Cr | — |
| Change In Inventory | -450.81 Cr | -513.86 Cr | -375.17 Cr | -203.42 Cr | — |
| Change In Receivables | -1.42K Cr | 969.51 Cr | -848.74 Cr | -549.27 Cr | — |
| Other Non Cash Items | 535.95 Cr | 1.40K Cr | 1.09K Cr | 467.04 Cr | — |
| Stock Based Compensation | -9.17 Cr | 4.96 Cr | 6.77 Cr | 7.92 Cr | — |
| Provisionand Write Offof Assets | 3.30 Cr | -4.23 Cr | 12.02 Cr | 15.13 Cr | — |
| Depreciation And Amortization | 486.01 Cr | 630.81 Cr | 611.27 Cr | 486.71 Cr | — |
| Depreciation | 486.01 Cr | 630.81 Cr | 381.01 Cr | 486.71 Cr | — |
| Pension And Employee Benefit Expense | 34.84 Cr | 49.65 Cr | 41.49 Cr | 46.58 Cr | — |
| Gain Loss On Investment Securities | -2.43 Cr | -752.01 Cr | -0.38 Cr | -15.33 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -69.06 Cr | -342.59 Cr | -286.16 Cr | -227.41 Cr | — |
| Gain Loss On Sale Of PPE | 2.54 Cr | -0.83 Cr | -5.72 Cr | 6.46 Cr | — |
| Net Income From Continuing Operations | 1.40K Cr | 569.19 Cr | 868.45 Cr | 1.44K Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | -191.76 Cr | 0.67 Cr | — | — |
| Net Other Financing Charges | — | — | -152.73 Cr | -57.39 Cr | — |
| Amortization Cash Flow | — | — | 230.26 Cr | — | — |
| Capital Expenditure Reported | — | — | — | — | -774.76 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Glenmark Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.